Skip to main content
. 2019 Sep 23;129(11):4593–4608. doi: 10.1172/JCI120879

Figure 6. KDR is not required for ANGPTL4 promotion of EC permeability.

Figure 6

(A) HUVECs were transfected with 50 nM scrambled (Scr) siRNA (si) or 50 nM KDR siRNA. Inhibition of KDR expression using Western blot is shown. (B) EC permeability assay upon transfection of scrambled siRNA or KDR siRNA and treatment with (5 μg/mL) rhANGPTL4 or (50 ng/mL) rhVEGFA or no treatment (control) in HUVECs. (C) EC permeability assay upon treatment with 5 μg/mL rhANGPTL4 or 50 ng/mL rhVEGFA or no treatment (control) of HUVECs pretreated (30 minutes) with SU1489. (D) Lack of immunoprecipitation of endogenous KDR with ANGPTL4 upon transfection of pcDNA3.1-ANGPTL4-mycHis in HUVECs. Transfection of pcDNA3.1-VEGFA is used as control. (E) EC permeability assay upon transfection of scrambled siRNA or KDR siRNA and treatment with 5 μg/mL rhANGPTL4, rhcANGPTL4,or rhnANGPTL4 or none (control) in HUVECs. (F) EC permeability upon treatment with (5 μg/mL) rhANGPTL4, rhcANGPTL4, or rhnANGPTL4 or none (control) in HUVECs pretreated (30 minutes) with SU1489. For SU1489 dose response, cells were pretreated with 0.01. 0.1, or 1 μM of drug (black bars) compared with vehicle (white bars). One-way ANOVA (B, C, E, F). *P < 0.05; ***P < 0.001. Experiments were repeated at least 3 times.